Correlation between the number of laparoscopy‐qualified gynecologists and the proportion of laparoscopic surgeries for benign gynecological diseases in Japan: An ecological study

2020 ◽  
Vol 47 (1) ◽  
pp. 329-336
Author(s):  
Masanori Isobe ◽  
Yuki Kataoka ◽  
Kenro Chikazawa ◽  
Tomonori Hada ◽  
Hiroshi Nishigori ◽  
...  
Keyword(s):  
Ecological Study ◽  
Gynecological Diseases ◽  
Benign Gynecological Diseases

scholarly journals Analytical and clinical evaluation of an electrochemiluminescence immunoassay for the determination of CA 125

1998 ◽  
Vol 44 (12) ◽  
pp. 2530-2536 ◽  
Author(s):  
Huub E van Ingen ◽  
Daniel W Chan ◽  
Walter Hubl ◽  
Hayato Miyachi ◽  
Rafael Molina ◽  
...  
Keyword(s):  
Multicenter Trial ◽  
Ca 125 ◽  
Newly Diagnosed ◽  
Cutoff Value ◽  
Gynecological Diseases ◽  
Electrochemiluminescence Immunoassay ◽  
Benign Gynecological Diseases ◽  
International Multicenter ◽  
Apparently Healthy

Abstract The CA 125 II assay on the Elecsys® 2010 analyzer was evaluated in an international multicenter trial. Imprecision studies yielded within-run CVs of 0.8–3.3% and between-day CVs of 2.4–10.9%; CVs for total imprecision in the manufacturer’s laboratory were 2.4–7.8%. The linear range of the assay extended to at least 4500 kilounits/L (three decades). Interference from triglycerides (10.3 mmol/L), bilirubin (850 μmol/L), hemoglobin (1.1 mmol/L), anticoagulants (plasma), and several widely used drugs was undetectable. Method comparisons with five other CA 125 II assays showed good correlation but differences in standardization. A 95th percentile cutoff value of 35 kilounits/L was calculated from values measured in 593 apparently healthy (pre- and postmenopausal) women. In 95% of patients with benign gynecological diseases CA 125 was ≤190 kilounits/L; 63% of patients with newly diagnosed ovarian carcinoma had values >190 kilounits/L. A comparison of CA 125 values obtained with the Elecsys test and with other common CA 125 tests in monitored patients being treated for ovarian cancer showed identical patterns. In conclusion, the Elecsys CA 125 II assay is linear over a broad range, yields precise and accurate results, is free from interferences, and compares well with other assays.

scholarly journals A Retrospective Review: Vaginal versus Abdominal Hysterectomy for Benign Gynecological Diseases in a Tertiary Canter

2016 ◽  
Vol 06 (12) ◽  
pp. 761-768
Author(s):  
Lujain Bukhari ◽  
Ayman A. Bukhari ◽  
Omar F. Albakri ◽  
Arwa F. Alshamrani ◽  
Walaa E. Alahmadi ◽  
...  
Keyword(s):  
Retrospective Review ◽  
Abdominal Hysterectomy ◽  
Gynecological Diseases ◽  
Benign Gynecological Diseases

P–454 Oocyte vitrification for fertility preservation in women with benign gynecological disease: French national clinical guidelines with a modified Delphi consensus process

2021 ◽  
Vol 36 (Supplement_1) ◽  
Author(s):  
B Courbière ◽  
E L Roux ◽  
E Mathie. D’Argent ◽  
A Torre ◽  
C Patrat ◽  
...  
Keyword(s):  
Fertility Preservation ◽  
Ovarian Reserve ◽  
Healthcare Professionals ◽  
Diminished Ovarian Reserve ◽  
Oocyte Vitrification ◽  
Modified Delphi ◽  
Gynecological Diseases ◽  
Gynecological Disease ◽  
Benign Gynecological Disease ◽  
Benign Gynecological Diseases

Abstract Study question Is there consensual clinical practices about fertility preservation (FP) for benign gynecological diseases BGD)? Summary answer A consensus study using the modified Delphi method identified 28 consensual practices concerning oocyte vitrification for fertility preservation in women with benign gynecological disease. What is known already Clinical Practical international guidelines are still published in oncology for offering standardized information and care for adults and children with cancer. Recently, the ESHRE Female Fertility Preservation Guideline Development Group published recommendations for healthcare professionals involved in fertility preservation for post-pubertal women and transgender adolescents and young adults. However, benign gynecological indications weren’t distinctly individualized of malignant conditions. There’s a lack of large cohort studies assessing the risks and outcome of FP for benign gynecological diseases. Healthcare professionals need consensus for defining the “good” indications of FP for benign gynecological diseases that could impair fertility. Study design, size, duration A steering group composed by 14 healthcare professionals and a patient representative with lived experience of endometriosis identified 42 potential practices concerning fertility preservation for benign gynecological disease. Then, 114 key stakeholders including various healthcare professionals (n = 108) and patient representatives(n = 6) were asked to answer at two rounds of a modified Delphi via an online survey from February to September 2020. Participants/materials, setting, methods Participants had to score 42 items for the first round and 31 for the second round using a nine-point Likert scale. These statements were distributed into five categories: Information to deliver to age-reproductive women with a BGD (n = 9), technical aspect of fertility preservation for BGD (n = 6), indications of FP for endometriosis (n = 13), indications of FP for none-endometriosis BGD (n = 10), idiopathic diminished ovarian reserve in the absence of gynecologic and endocrinologic diseases (n = 4). Main results and the role of chance Survey response of stakeholders was 75% (86 out of 114) for the round 1 and 87% (75 out of 86) for the round 2. Consensus recommendations were achieved for 28 items, and no consensus between stakeholders was achieved in the remaining items. Stakeholders rated the importance of an age-specific information concerning the risk of diminished ovarian reserve after surgery and the necessity to inform about the benefice/ risk balance of oocyte vitrification, in particular about the chance of live-birth according to the age at the time of oocyte vitrification. They endorsed oocyte vitrification as the reference FP technique for those benign indications. Experts rejected to determine lower and upper age limits in women for fertility preservation. FP shouldn’t be offered in rAFS stages I and II endometriosis without endometriomas. Limitations, reasons for caution Experts were only French native speakers from France, and Belgium. It would have been interesting to conduct this survey with experts from other continents. Wider implications of the findings: At our knowledge, we present here the first guideline s focusing on FP in women with BGD, following a designed scientific Delphi procedure. These guidelines could be useful for gynecologists to better inform women with benign gynecological diseases about the indication or not to offer a FP procedure. Trial registration number Not applicable

Sign in / Sign up

Export Citation Format

Share Document